Skip to content

8-KAccepted Oct 15, 4:20 PM ET

Halliburton Co: appoints David C. Hernandez to board

HALHALLIBURTON CO

Accepted (ET)

4:20 PM

Oct 15, 2026

Filed

Oct 15, 2026

Documents

15

Size

550.3 KB

Summary

Halliburton Co: appoints David C. Hernandez to board

Updated

What happened

  • On Oct 15, 2026 the board appointed David C. Hernandez as a member of the board to fill a vacancy; the board size remains at 12 directors.
  • The board appointed Mr. Hernandez to the audit committee and the health, safety and environment committee and designated him an "audit committee financial expert."
  • Halliburton entered into an indemnification agreement with Mr. Hernandez on Oct 15, 2026. The company furnished a press release about the appointment as Exhibit 99.1.

Key details

  • Mr. Hernandez currently serves as President and Director of Hunt Consolidated, Inc.; he served as President since 2025 and during 2019-2022, and as Chairman and Managing Director during 2023-2024. He previously served as Vice President of Tax for Electronic Data Systems. He holds a J.D. from The University of Chicago and a B.S. in finance from the University of Virginia McIntire School of Commerce.
  • The board moved Timothy A. Leach from the audit committee and appointed him to the compensation committee in connection with Mr. Hernandez’s committee assignments.
  • Mr. Hernandez will participate in non-management director compensation and will receive an initial equity award of restricted stock units equal to the prorated value of the $200,000 annual equity award for non-management directors; based on the company’s formula he will receive 961 RSUs.
  • The indemnification agreement provides that Halliburton will indemnify and advance certain expenses to Mr. Hernandez to the fullest extent permitted by applicable law.

Why it may matter

  • This report was made under Item 5.02 (departure of directors or certain officers; election of directors) and Item 7.01 (regulation FD disclosure of a press release). Item 5.02 covers the appointment, committee assignments, director independence designation, compensation arrangements and the indemnification agreement described above. The filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing